WolverHeme Happy Hour
Un podcast de Bernard Marini, Anthony Perissinotti, et al.
35 Épisodes
-
Dex and the Cytokine City: Managing CRS with Bispecifics
Publié: 07/04/2025 -
LFGooo! The Rise, the Fall, and the Resurrection of Gemtuzumab in AML
Publié: 11/03/2025 -
Episode 32: Navigating a BlinatumoMAD World
Publié: 21/01/2025 -
The Aquila Study: Blowing Hot Air or a Soaring Success for Smoldering Multiple Myeloma
Publié: 15/01/2025 -
Pour Decisions, or ASH-olutely Fabulous? Reviewing 2024 ASH Lymphoma Updates
Publié: 24/12/2024 -
A Bunch of ASHholes Discuss Myeloma Abstracts
Publié: 16/11/2024 -
Cast your vote! Nivolumab vs. Brentuximab for Classical Hodgkin Lymphoma
Publié: 08/11/2024 -
Episode 27: Mantle Cell Masterclass with Tycel Phillips
Publié: 10/10/2024 -
Houston, we don't have a problem... with APOLLO
Publié: 28/08/2024 -
From Ancient Remedies to Modern Miracles: The Evolution of APL Treatment
Publié: 13/06/2024 -
Episode 24: Myeloma Madness with the Myeloma Man
Publié: 17/04/2024 -
Anthony and Bernie get rich on no-larabine! An ASH 2023 ALL discussion
Publié: 25/01/2024 -
LymphOMG: Pouring Over Lymphoma Abstracts from ASH
Publié: 29/12/2023 -
AMLchemy at ASH: Brewing Success with Menin Magic, MRD Mysteries, and Aza/Ven Alchemy
Publié: 19/12/2023 -
ASH Pregaming - Myeloma Madness with Manni and Papa Heme
Publié: 01/12/2023 -
AML Maintenance Part 2: a metaMORPHOsis?
Publié: 08/11/2023 -
AML Maintenance Part 1: Set Your QUAZARs to Stun
Publié: 25/10/2023 -
Episode 17: The Hemophilia Eras Tour
Publié: 23/08/2023 -
Common Sense Oncology: Outcomes That Matter
Publié: 01/08/2023 -
All too well: the reality of leukemia treatment
Publié: 08/06/2023
Welcome to WolverHeme Happy Hour! This is a podcast dedicated to all things hematology! We discuss new data, debate controversial therapies, and talk about new and exciting research. While we nerd out about data, we'll have a few drinks! Disclaimer: The views and opinions expressed on this podcast are solely those of the podcasters and guests and do not reflect the views or opinions of our employers or other affiliations.
